Capricor Therapeutics, Inc.
NASDAQ:CAPRBiotechnology
-$0.14 today
- Market cap
- $465.03M
- Beta
- 0.37
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$2.00
Volume 8.33M
Average 1.08M
CAPR Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Capricor Therapeutics, Inc.NASDAQ: CAPR
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin not reported for Q1 FY2026
Context
- Operating margin widened in 1 of the last 2 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2024
- -191.1%
- Year-over-year change
- -95.5pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | — | — |
| FY2024 | 2024-12-31 | -191.1% | -95.5pp |
| FY2023 | 2023-12-31 | -95.6% | +1068.3pp |
| FY2022 | 2022-12-31 | -1163.9% | +7385.9pp |
| FY2021 | 2021-12-31 | -8549.9% | — |
Operating Margin vs competitors
How CAPR compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 11.5% | -29.2 pp | +113.5 pp | |
| LTM Mar 2026 | -1.9% | +3.4 pp | +27.5 pp | |
| LTM Sep 2026 | -58.9% | -30.2 pp | +29.4 pp | |
| LTM Mar 2026 | -274.2% | -154.4 pp | +3955.2 pp | |
| LTM Mar 2026 | -3109.3% | -3111.7 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CAPR) | -58.9% | -30.2 pp | +71.4 pp | |
Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 244.9K | 2.55M | 25.18M | 22.27M | 0 |
| Cost of Revenue | 0 | 21.82M | 36.45M | 49.97M | 0 |
| Gross Profit | 244.9K | (19.27M) | (11.27M) | (27.7M) | 0 |
| Gross Margin | 100.0% | -755.1% | -44.8% | -124.4% | — |
| Research & Development | 13.57M | 21.82M | 36.45M | 49.97M | 84.45M |
| Selling, General & Admin | 7.61M | 10.43M | 12.81M | 14.87M | 22.75M |
| Operating Expenses | 21.18M | 10.43M | 12.81M | 14.87M | 108.14M |
| Depreciation & Amortization | 245.7K | 533.13K | 1.07M | 1.43M | 1.89M |
| EBITDA | (19.78M) | (28.49M) | (21.22M) | (39.04M) | (100.11M) |
| EBITDA Margin | -8075.5% | -1116.5% | -84.3% | -175.3% | — |
| Operating Income | (20.94M) | (29.7M) | (24.08M) | (42.56M) | (108.14M) |
| Operating Margin | -8549.9% | -1163.9% | -95.6% | -191.1% | — |
| Interest Income | 0 | 521.53K | 1.73M | 2.2M | 6.26M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.05M |
| Other Income / Expenses | 915.92K | 677.85K | 1.79M | 2.1M | 3.1M |
| Income Before Tax | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Pre-Tax Margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Net Margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| EPS (Basic) | (0.87) | (1.18) | (0.83) | (1.15) | (2.26) |
| EPS (Diluted) | (0.87) | (1.18) | (0.83) | (1.15) | (2.26) |
| Weighted Avg Shares | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M |
| Weighted Avg Shares (Diluted) | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M |
Capricor Therapeutics, Inc.
NASDAQ:CAPR
Intrinsic Alpha fair value
Locked
Current Price
$8.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.